Novo Nordisk appoints ex-Pfizer head
pharmafile | May 10, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novo Nordisk, Pfizer, Robert Clark, regulatory affairs
Robert Clark will be joining Novo Nordisk as vice president, regulatory affairs.
Clark will lead Novo Nordisk’s US regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the FDA’s review and approval process.
“Bob is bringing 27 years of experience and knowledge of the global and US regulatory environment, and it’s that know-how we require for an increasingly complex pharmaceutical marketplace,” said Anne Philips, corporate vice president, Clinical Development, Medical and Regulatory Affairs.
Clark comes to Novo Nordisk from Pfizer, where he was US Regulatory Strategy Head. During his time at Pfizer, he led or supported approvals of new medicines in cardiovascular, endocrine, women’s health and anti-infective therapy areas. Additionally, he is an expert on US pharmaceutical advertising and promotional practices.
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …






